Try a new search

Format these results:

Searched for:

in-biosketch:true

person:moyl02

Total Results:

249


Harmonizing Breast Cancer Screening Recommendations: Metrics and Accountability

Lee, Cindy S; Moy, Linda; Friedewald, Sarah M; Sickles, Edward A; Monticciolo, Debra L
OBJECTIVE: The purposes of this article are to summarize breast cancer screening recommendations and discuss their differences and similarities and to explain the differences between two national databases to aid in interpretation of their benchmarks. CONCLUSION: The American College of Radiology, American Cancer Society, and U.S. Preventive Services Task Force all agree that annual mammography beginning at age 40 saves the most lives, and all acknowledge a woman's right to choose when to begin and stop screening. The National Mammography Database (NMD) differs from the Breast Cancer Surveillance Consortium database in that it acquires data using the same approach used by almost all mammography facilities in the United States. Therefore, NMD benchmarks, which include standard metrics, provide more meaningful comparisons to help mammography facilities and radiologists improve performance.
PMID: 29045178
ISSN: 1546-3141
CID: 2776792

Screening for Breast Cancer in Women Age 75 Years and Older

Lee, Cindy S; Moy, Linda; Joe, Bonnie N; Sickles, Edward A; Niell, Bethany L
OBJECTIVE: Older women undergoing regular mammography experience significant reductions in breast cancer mortality, except in women with severe comorbidities or limited life expectancy. Optimizing screening strategies requires informed discussions of benefits and risks given each woman's health status. CONCLUSION: This article will review the benefits and risks of screening mammography in women older than 75 years within the context of life expectancy and comorbidities and summarize the current recommendations from professional organizations for screening mammography in older women.
PMID: 29112471
ISSN: 1546-3141
CID: 2773062

BREAST DENSITY CLASSIFICATION WITH DEEP CONVOLUTIONAL NEURAL NETWORKS

Chapter by: Wu, Nan; Geras, Krzysztof J.; Shen, Yiqiu; Su, Jingyi; Kim, Gene; Kim, Eric; Wolfson, Stacey; Moy, Linda; Cho, Kyunghyun
in: 2018 IEEE INTERNATIONAL CONFERENCE ON ACOUSTICS, SPEECH AND SIGNAL PROCESSING (ICASSP) by
NEW YORK : IEEE, 2018
pp. 6682-6686
ISBN: 978-1-5386-4658-8
CID: 3496792

Do Tumor Shrinkage Patterns at Breast MR Imaging Predict Survival?

Moy, Linda
PMID: 29261475
ISSN: 1527-1315
CID: 2892482

ACR Appropriateness Criteria(R) Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer

Slanetz, Priscilla J; Moy, Linda; Baron, Paul; diFlorio, Roberta M; Green, Edward D; Heller, Samantha L; Holbrook, Anna I; Lee, Su-Ju; Lewin, Alana A; Lourenco, Ana P; Niell, Bethany; Stuckey, Ashley R; Trikha, Sunita; Vincoff, Nina S; Weinstein, Susan P; Yepes, Monica M; Newell, Mary S
Patients with locally advanced invasive breast cancers are often treated with neoadjuvant chemotherapy prior to definitive surgical intervention. The primary aims of this approach are to: 1) reduce tumor burden thereby permitting breast conservation rather than mastectomy; 2) promptly treat possible metastatic disease, whether or not it is detectable on preoperative staging; and 3) potentially tailor future chemotherapeutic decisions by monitoring in-vivo tumor response. Accurate radiological assessment permits optimal management and planning in this population. However, assessment of tumor size and response to treatment can vary depending on the modality used, the measurement technique (such as single longest diameter, 3-D measurements, or calculated tumor volume), and varied response of different tumor subtypes to neoadjuvant chemotherapy (such as concentric shrinkage or tumor fragmentation). As discussed in further detail, digital mammography, digital breast tomosynthesis, US and MRI represent the key modalities with potential to help guide patient management. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
PMID: 29101985
ISSN: 1558-349x
CID: 2772202

ACR Appropriateness Criteria(R) Breast Cancer Screening

Mainiero, Martha B; Moy, Linda; Baron, Paul; Didwania, Aarati D; diFlorio, Roberta M; Green, Edward D; Heller, Samantha L; Holbrook, Anna I; Lee, Su-Ju; Lewin, Alana A; Lourenco, Ana P; Nance, Kara J; Niell, Bethany L; Slanetz, Priscilla J; Stuckey, Ashley R; Vincoff, Nina S; Weinstein, Susan P; Yepes, Monica M; Newell, Mary S
Breast cancer screening recommendations are based on risk factors. For average-risk women, screening mammography and/or digital breast tomosynthesis is recommended beginning at age 40. Ultrasound (US) may be useful as an adjunct to mammography for incremental cancer detection in women with dense breasts, but the balance between increased cancer detection and the increased risk of a false-positive examination should be considered in the decision. For intermediate-risk women, US or MRI may be indicated as an adjunct to mammography depending upon specific risk factors. For women at high risk due to prior mantle radiation between the ages of 10 to 30, mammography is recommended starting 8 years after radiation therapy but not before age 25. For women with a genetic predisposition, annual screening mammography is recommended beginning 10 years earlier than the affected relative at the time of diagnosis but not before age 30. Annual screening MRI is recommended in high-risk women as an adjunct to mammography. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.
PMID: 29101979
ISSN: 1558-349x
CID: 2772232

Comprehensive Dynamic Contrast-Enhanced 3D Magnetic Resonance Imaging of the Breast With Fat/Water Separation and High Spatiotemporal Resolution Using Radial Sampling, Compressed Sensing, and Parallel Imaging

Benkert, Thomas; Block, Kai Tobias; Heller, Samantha; Moccaldi, Melanie; Sodickson, Daniel K; Kim, Sungheon Gene; Moy, Linda
OBJECTIVES: The aim of this study was to assess the applicability of Dixon radial volumetric encoding (Dixon-RAVE) for comprehensive dynamic contrast-enhanced 3D magnetic resonance imaging (MRI) of the breast using a combination of radial sampling, model-based fat/water separation, compressed sensing, and parallel imaging. MATERIALS AND METHODS: In this Health Insurance Portability and Accountability Act-compliant prospective study, 24 consecutive patients underwent bilateral breast MRI, including both conventional fat-suppressed and non-fat-suppressed precontrast T1-weighted volumetric interpolated breath-hold examination (VIBE). Afterward, 1 continuous Dixon-RAVE scan was performed with the proposed approach while the contrast agent was injected. This scan was immediately followed by the acquisition of 4 conventional fat-saturated VIBE scans. From the comprehensive Dixon-RAVE data set, different image contrasts were reconstructed that are comparable to the separate conventional VIBE scans.Two radiologists independently rated image quality, conspicuity of fibroglandular tissue from fat (FG), and degree of fat suppression (FS) on a 5-point Likert-type scale for the following 3 comparisons: precontrast fat-suppressed (pre-FS), precontrast non-fat-suppressed (pre-NFS), and dynamic fat-suppressed (dyn-FS) images. RESULTS: When scores were averaged over readers, Dixon-RAVE achieved significantly higher (P < 0.001) degree of fat suppression compared with VIBE, for both pre-FS (4.25 vs 3.67) and dyn-FS (4.10 vs 3.46) images. Although Dixon-RAVE had lower image quality score compared with VIBE for the pre-FS (3.56 vs 3.67, P = 0.490), the pre-NFS (3.54 vs 3.88, P = 0.009), and the dyn-FS images (3.06 vs 3.67, P < 0.001), acceptable or better diagnostic quality was achieved (score >/= 3). The FG score for Dixon-RAVE in comparison to VIBE was significantly higher for the pre-FS image (4.23 vs 3.85, P = 0.044), lower for the pre-NFS image (3.98 vs 4.25, P = 0.054), and higher for the dynamic fat-suppressed image (3.90 vs 3.85, P = 0.845). CONCLUSIONS: Dixon-RAVE can serve as a one-stop-shop approach for comprehensive T1-weighted breast MRI with diagnostic image quality, high spatiotemporal resolution, reduced overall scan time, and improved fat suppression compared with conventional imaging.
PMCID:5585043
PMID: 28398929
ISSN: 1536-0210
CID: 2528202

Compressed Sensing for Breast MRI: Resolving the Trade-Off Between Spatial and Temporal Resolution

Vreemann, Suzan; Rodriguez-Ruiz, Alejandro; Nickel, Dominik; Heacock, Laura; Appelman, Linda; van Zelst, Jan; Karssemeijer, Nico; Weiland, Elisabeth; Maas, Marnix; Moy, Linda; Kiefer, Berthold; Mann, Ritse M
OBJECTIVE: Ultrafast dynamic contrast-enhanced magnetic resonance imaging of the breast enables assessment of the contrast inflow dynamics while providing images with diagnostic spatial resolution. However, the slice thickness of common ultrafast techniques still prevents multiplanar reconstruction. In addition, some temporal blurring of the enhancement characteristics occurs in case view-sharing is used. We evaluate a prototype compressed-sensing volume-interpolated breath-hold examination (CS-VIBE) sequence for ultrafast breast MRI that improves through plane spatial resolution and avoids temporal blurring while maintaining an ultrafast temporal resolution (less than 5 seconds per volume). Image quality (IQ) of the new sequence is compared with an ultrafast view-sharing sequence (time-resolved angiography with interleaved stochastic trajectories [TWIST]), and assessment of lesion morphology is compared with a regular T1-weighted 3D Dixon sequence (VIBE-DIXON) with an acquisition time of 91 seconds. MATERIALS AND METHODS: From April 2016 to October 2016, 30 women were scanned with the CS-VIBE sequence, replacing the routine ultrafast TWIST sequence in a hybrid breast MRI protocol. The need for informed consent was waived. All MRI scans were performed on a 3T MAGNETOM Skyra system (Siemens Healthcare, Erlangen, Germany) using a 16-channel bilateral breast coil. Two reader studies were conducted involving 5 readers. In the first study, overall IQ of CS-VIBE and TWIST in the axial plane was independently rated for 23 women for whom prior MRI examinations with TWIST were available. In addition, the presence of several types of artifacts was rated on a 5-point scale. The second study was conducted in women (n = 16) with lesions. In total, characteristics of 31 lesions (5 malignant and 26 benign) were described independently for CS-VIBE and VIBE-DIXON, according to the BI-RADS MRI-lexicon. In addition, a lesion conspicuity score was given. RESULTS: Using CS-VIBE, a much higher through-plane spatial resolution was achieved in the same acquisition time as with TWIST, without affecting in-plane IQ (P = 0.260). Time-resolved angiography with interleaved stochastic trajectories showed slightly more motion artifacts and infolding and ghosting artifacts compared with CS-VIBE, whereas CS-VIBE showed more breathing and pulsation artifacts. For morphologic assessment, intrareader agreement between CS-VIBE and the more time-consuming VIBE-DIXON was slight to almost perfect, and generally higher than interreader agreement. Mean sensitivity (84.0% and 92.0% for CS-VIBE and VIBE-DIXON, P = 0.500) and specificity (60.0% and 55.4% for CS-VIBE and VIBE-DIXON, P = 0.327) were comparable for both sequences. CONCLUSIONS: Compressed-sensing volume-interpolated breath-hold examination allows an increase of the through-plane spatial resolution of ultrafast dynamic contrast-enhanced magnetic resonance imaging compared with TWIST at a comparable in-plane IQ. Morphological assessment of lesions using CS-VIBE is comparable to VIBE-DIXON, which takes 18 times longer. Consequently, CS-VIBE enables 3D evaluation of breast lesions in ultrafast breast MRI.
PMID: 28463932
ISSN: 1536-0210
CID: 2546492

Voxelwise analysis of simultaneously acquired and spatially correlated 18 F-fluorodeoxyglucose (FDG)-PET and intravoxel incoherent motion metrics in breast cancer

Ostenson, Jason; Pujara, Akshat C; Mikheev, Artem; Moy, Linda; Kim, Sungheon G; Melsaether, Amy N; Jhaveri, Komal; Adams, Sylvia; Faul, David; Glielmi, Christopher; Geppert, Christian; Feiweier, Thorsten; Jackson, Kimberly; Cho, Gene Y; Boada, Fernando E; Sigmund, Eric E
PURPOSE: Diffusion-weighted imaging (DWI) and 18 F-fluorodeoxyglucose-positron emission tomography (18 F-FDG-PET) independently correlate with malignancy in breast cancer, but the relationship between their structural and metabolic metrics is not completely understood. This study spatially correlates diffusion, perfusion, and glucose avidity in breast cancer with simultaneous PET/MR imaging and compares correlations with clinical prognostics. METHODS: In this Health Insurance Portability and Accountability Act-compliant prospective study, with written informed consent and approval of the institutional review board and using simultaneously acquired FDG-PET and DWI, tissue diffusion (Dt ), and perfusion fraction (fp ) from intravoxel incoherent motion (IVIM) analysis were registered to FDG-PET within 14 locally advanced breast cancers. Lesions were analyzed using 2D histograms and correlation coefficients between Dt , fp , and standardized uptake value (SUV). Correlations were compared with prognostics from biopsy, metastatic burden from whole-body PET, and treatment history. RESULTS: SUV||Dt correlation coefficient significantly distinguished treated (0.11 +/- 0.24) from nontreated (-0.33 +/- 0.26) patients (P = 0.005). SUV||fp correlations were on average negative for the whole cohort (-0.17 +/- 0.13). CONCLUSION: Simultaneously acquired and registered FDG-PET/DWI allowed quantifiable descriptions of breast cancer microenvironments that may provide a framework for monitoring and predicting response to treatment. Magn Reson Med, 2016. (c) 2016 International Society for Magnetic Resonance in Medicine.
PMCID:5405014
PMID: 27779790
ISSN: 1522-2594
CID: 2288692

Breast Cancer Screening for Average-Risk Women: Recommendations From the ACR Commission on Breast Imaging

Monticciolo, Debra L; Newell, Mary S; Hendrick, R Edward; Helvie, Mark A; Moy, Linda; Monsees, Barbara; Kopans, Daniel B; Eby, Peter R; Sickles, Edward A
Breast cancer is the most common non-skin cancer and the second leading cause of cancer death for women in the United States. Before the introduction of widespread mammographic screening in the mid-1980s, the death rate from breast cancer in the US had remained unchanged for more than 4 decades. Since 1990, the death rate has declined by at least 38%. Much of this change is attributed to early detection with mammography. ACR breast cancer screening experts have reviewed data from RCTs, observational studies, US screening data, and other peer-reviewed literature to update our recommendations. Mammography screening has consistently been shown to significantly reduce breast cancer mortality over a variety of study designs. The ACR recommends annual mammography screening starting at age 40 for women of average risk of developing breast cancer. Our recommendation is based on maximizing proven benefits, which include a substantial reduction in breast cancer mortality afforded by regular screening and improved treatment options for those diagnosed with breast cancer. The risks associated with mammography screening are also considered to assist women in making an informed choice.
PMID: 28648873
ISSN: 1558-349x
CID: 2614522